Tehran – The Razi Vaccine and Serum Research Institute recently hosted a national seminar on avian influenza, bringing together over 400 experts from academia, industry, and government.

The event, held on October 21st at the Mirshamsi Conference Hall, focused on the latest research findings and strategies to combat this significant threat to poultry health.

A major highlight of the seminar was the unveiling of a groundbreaking achievement: the development of a recombinant seed for the highly pathogenic avian influenza (H5) vaccine. This innovative vaccine, the first of its kind in Iran, is produced using circulating native viruses and offers robust immunity against wild strains while posing minimal risk to poultry.

Dr. Ali Es-haghi, Director-General of Razi Institute, emphasized the institute’s role as a leading scientific center in veterinary disease research and vaccine production. He highlighted the importance of vaccines in ensuring food security and addressing global concerns about avian influenza outbreaks.

The institute has also made significant strides in the fight against COVID-19, having successfully developed the second-generation vaccine, Razi Cov-Pars.